Short Interest in CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Drops By 14.2%

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) was the target of a significant drop in short interest in March. As of March 31st, there was short interest totaling 414,235 shares, a drop of 14.2% from the March 15th total of 483,060 shares. Based on an average trading volume of 128,124 shares, the short-interest ratio is presently 3.2 days. Currently, 1.2% of the company’s stock are short sold.

CAMP4 Therapeutics Trading Down 0.2%

CAMP stock opened at $4.49 on Friday. The firm has a market cap of $233.12 million, a PE ratio of -1.69 and a beta of 0.41. CAMP4 Therapeutics has a 1 year low of $1.30 and a 1 year high of $7.75. The company has a fifty day simple moving average of $4.64 and a 200 day simple moving average of $4.51.

CAMP4 Therapeutics (NASDAQ:CAMP) last posted its earnings results on Thursday, March 5th. The Wireless communications provider reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.56). CAMP4 Therapeutics had a negative return on equity of 162.49% and a negative net margin of 2,298.54%.The business had revenue of $0.35 million for the quarter. As a group, analysts forecast that CAMP4 Therapeutics will post -4.99 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on CAMP. Cantor Fitzgerald restated an “overweight” rating on shares of CAMP4 Therapeutics in a research note on Friday, March 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CAMP4 Therapeutics in a research note on Monday, December 29th. Leerink Partners boosted their price target on CAMP4 Therapeutics from $8.00 to $9.00 and gave the company an “outperform” rating in a research note on Thursday, April 2nd. Finally, Rodman & Renshaw assumed coverage on CAMP4 Therapeutics in a report on Tuesday. They issued a “buy” rating and a $7.00 price objective on the stock. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $8.60.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CAMP. Bank of America Corp DE acquired a new stake in CAMP4 Therapeutics in the 4th quarter worth approximately $86,000. Bridgeway Capital Management LLC acquired a new position in CAMP4 Therapeutics during the second quarter valued at approximately $36,000. Two Sigma Investments LP bought a new position in shares of CAMP4 Therapeutics in the third quarter valued at approximately $292,000. Vivo Capital LLC bought a new position in shares of CAMP4 Therapeutics in the third quarter valued at approximately $11,765,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in shares of CAMP4 Therapeutics in the fourth quarter worth $61,000.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.